Novel routes to bipolar disorder drug discovery

Expert Opinion on Drug Discovery

Volumn 8, Issue 8, 2013, Pages 907-918

  Hoertel, Nicolas ^a,b,d   De Maricourt, Pierre ^c,d   Gorwood, Philip ^b,c,d  

^a Paris Descartes University   (France)

^b INSERM   (France)

^c CMME   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Bipolar disorder; Drug discovery; Target; Treatment

Indexed keywords

ACETYLCYSTEINE; BRAIN DERIVED NEUROTROPHIC FACTOR; CALCIUM ION; GLUTAMIC ACID; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3BETA; INSULIN; KETAMINE; LITHIUM; MELATONIN; MEMANTINE; MITOGEN ACTIVATED PROTEIN KINASE; MOOD STABILIZER; PHOSPHATIDYLINOSITIDE; PROTEIN KINASE C; VERAPAMIL;

APOPTOSIS; BIPOLAR DISORDER; BLOOD BRAIN BARRIER; DEPOLARIZATION; ENZYME ACTIVATION; ENZYME INHIBITION; GENE MUTATION; MITOCHONDRIAL MEMBRANE; MITOCHONDRION; NONHUMAN; PATHOPHYSIOLOGY; PHARMACOGENETICS; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PREFRONTAL CORTEX; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; BIPOLAR DISORDER; DRUG DISCOVERY; HUMANS; PSYCHOTROPIC DRUGS;

EID: 84880732177     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2013.804057     Document Type: Review

References (68)

1. Frye MA. Clinical practice. Bipolar disorder-a focus on depression. N Engl J Med Jan 2011;364(1):51-9
2. Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007;64(5):543-52
3. Hoertel N, Le Strat Y, Angst J, Dubertret C. Subthreshold bipolar disorder in a U.S. national representative sample: Prevalence, correlates and perspectives for psychiatric nosography. J Affect Disord 2013;146(3):338-47
4. Hoertel N, Le Strat Y, Limosin F, et al. Prevalence of subthreshold hypomania and impact on internal validity of RCTs for major depressive disorder: Results from a national epidemiological sample. PLoS One 2013;8(2):e55448
5. Smith LA, Cornelius V, Warnock A, et al. Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: A systematic review of randomized controlled trials. Bipolar Disord 2007;9(4):394-412
6. Beaulieu JM, Zhang X, Rodriguiz RM, et al. Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency. Proc Natl Acad Sci USA 2008;105(4):1333-8
7. Gould TD, Quiroz JA, Singh J, et al. Emerging experimental therapeutics for bipolar disorder: Insights from the molecular and cellular actions of current mood stabilizers. Mol Psychiatry 2004;9(8):734-55
8. McClung CA. Circadian genes, rhythms and the biology of mood disorders. Pharmacol Ther 2007;114(2):222-32
9. Roybal K, Theobold D, Graham A, et al. Mania-like behavior induced by disruption of CLOCK. Proc Natl Acad Sci USA 2007;104(15):6406-11
10. Soreca I, Fagiolini A, Frank E, et al. Relationship of general medical burden, duration of illness and age in patients with bipolar I disorder. J Psychiatr Res 2008;42(11):956-61
11. Bijur GN, Jope RS. Glycogen synthase kinase-3 beta is highly activated in nuclei and mitochondria. Neuroreport 2003;14(18):2415-19
12. Bertolino A, Frye M, Callicott JH, et al. Neuronal pathology in the hippocampal area of patients with bipolar disorder: A study with proton magnetic resonance spectroscopic imaging. Biol Psychiatry 2003;53(10):906-13
13. Andreazza AC, Shao L, Wang JF, Young LT. Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Arch Gen Psychiatry 2010;67(4):360-8
14. Linseman DA, Butts BD, Precht TA, et al. Glycogen synthase kinase-3beta phosphorylates Bax and promotes its mitochondrial localization during neuronal apoptosis. J Neurosci 2004;24(44):9993-10002
15. Bachmann RF, Schloesser RJ, Gould TD, Manji HK. Mood stabilizers target cellular plasticity and resilience cascades: Implications for the development of novel therapeutics. Mol Neurobiol 2005;32(2):173-202
16. Alsaif M, Haenisch F, Guest PC, et al. Challenges in drug target discovery in bipolar disorder. Expert Opin Ther Targets 2013;17(5):565-77
17. Gurvich N, Klein PS. Lithium and valproic acid: Parallels and contrasts in diverse signaling contexts. Pharmacol Ther 2002;96(1):45-66
18. Gould TD, Zarate CA, Manji HK. Glycogen synthase kinase-3: A target for novel bipolar disorder treatments. J Clin Psychiatry 2004;65(1):10-21
19. Rayasam GV, Tulasi VK, Sodhi R, et al. Glycogen synthase kinase 3: More than a namesake. Br J Pharmacol 2009;156(6):885-98
20. Machado-Vieira R, Salvadore G, DiazGranados N, et al. New therapeutic targets for mood disorders. ScientificWorldJournal 2010;10:713-26
21. Schloesser RJ, Huang J, Klein PS, Manji HK. Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology 2008;33(1):110-33
22. Gould TD, Einat H, Bhat R, Manji HK. AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol 2004;7(4):387-90
23. Manji HK, Lenox RH. Ziskind-Somerfeld Research Award. Protein kinase C signaling in the brain: Molecular transduction of mood stabilization in the treatment of manic-depressive illness. Biol Psychiatry 1999;46(10):1328-51
24. Mathew SJ, Manji HK, Charney DS. Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology 2008;33(9):2080-92
25. Stork C, Renshaw PF. Mitochondrial dysfunction in bipolar disorder: Evidence from magnetic resonance spectroscopy research. Mol Psychiatry 2005;10(10):900-19
26. Lan MJ, McLoughlin GA, Griffin JL, et al. Metabonomic analysis identifies molecular changes associated with the pathophysiology and drug treatment of bipolar disorder. Mol Psychiatry 2009;14(3):269-79
27. Kim H, McGrath BM, Silverstone PH. A review of the possible relevance of inositol and the phosphatidylinositol second messenger system (PI-cycle) to psychiatric disorders-focus on magnetic resonance spectroscopy (MRS) studies. Hum Psychopharmacol 2005;20(5):309-26
28. Einat H, Yuan P, Szabo ST, et al. Protein kinase C inhibition by tamoxifen antagonizes manic-like behavior in rats: Implications for the development of novel therapeutics for bipolar disorder. Neuropsychobiology 2007;55(3-4):123-31
29. Baum AE, Akula N, Cabanero M, et al. A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the
30. Du J, Suzuki K, Wei Y, et al. The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: Relationship to clinical effects in mood disorders. Neuropsychopharmacology 2007;32(4):793-802
31. Zarate CA Jr, Payne JL, Quiroz J, et al. An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry 2004;161(1):171-4
32. Sanacora G, Kendell SF, Levin Y, et al. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry 2007;61(6):822-5
33. Zarate CA Jr, Quiroz JA, Singh JB, et al. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry 2005;57(4):430-2
34. Lourenco Da Silva A, Hoffmann A, Dietrich MO, et al. Effect of riluzole on MK-801 and amphetamine-induced hyperlocomotion. Neuropsychobiology 2003;48(1):27-30
35. Black MD. Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data. Psychopharmacology (Berl) 2005;179(1):154-63
36. Charney DS, Manji HK. Life stress, genes, and depression: Multiple pathways lead to increased risk and new opportunities for intervention. Sci STKE 2004;2004(225):re5
37. Burdick KE, Braga RJ, Nnadi CU, et al. Placebo-controlled adjunctive trial of pramipexole in patients with bipolar disorder: Targeting cognitive dysfunction. J Clin Psychiatry 2012;73(1):103-12
38. Zarate CA Jr, Payne JL, Singh J, et al. Pramipexole for bipolar II depression: A placebo-controlled proof of concept study. Biol Psychiatry 2004;56(1):54-60
39. Berk M, Dean OM, Cotton SM, et al. Maintenance N-acetyl cysteine treatment for bipolar disorder: A double-blind randomized placebo controlled trial. BMC Med 2012;10:91
40. Nicoletti VG, Marino VM, Cuppari C, et al. Effect of antioxidant diets on mitochondrial gene expression in rat brain during aging. Neurochem Res 2005;30(6-7):737-52
41. Gawryluk JW, Wang JF, Andreazza AC, et al. Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int J Neuropsychopharmacol 2011;14(1):123-30
42. Berk M, Copolov DL, Dean O, et al. N-acetyl cysteine for depressive symptoms in bipolar disorder-a double-blind randomized placebo-controlled trial. Biol Psychiatry 2008;64(6):468-75
43. Winsberg ME, Sachs N, Tate DL, et al. Decreased dorsolateral prefrontal N-acetyl aspartate in bipolar disorder. Biol Psychiatry 2000;47(6):475-81
44. Forester BP, Zuo CS, Ravichandran C, et al. Coenzyme Q10 effects on creatine kinase activity and mood in geriatric bipolar depression. J Geriatr Psychiatry Neurol 2012;25(1):43-50
45. Post RM. Promising avenues of therapeutics for bipolar illness. Dialogues Clin Neurosci 2008;10(2):193-201
46. Maes M, Goossens F, Scharpe S, et al. Alterations in plasma prolyl endopeptidase activity in depression, mania, and schizophrenia: Effects of antidepressants, mood stabilizers, and antipsychotic drugs. Psychiatry Res 1995;58(3):217-25
47. Bahtiyar G, Weiss K, Sacerdote AS. Novel endocrine disrupter effects of classic and atypical antipsychotic agents and divalproex: Induction of adrenal hyperandrogenism, reversible with metformin or rosiglitazone. Endocr Pract 2007;13(6):601-8
48. Landreth G, Jiang Q, Mandrekar S, Heneka M. PPARgamma agonists as therapeutics for the treatment of Alzheimers disease. Neurotherapeutics 2008;5(3):481-9
49. McIntyre RS, Soczynska JK, Woldeyohannes HO, et al. A randomized, double-blind, controlled trial evaluating the effect of intranasal insulin on neurocognitive function in euthymic patients with bipolar disorder. Bipolar Disord 2012;14(7):697-706
50. Brietzke E, Kapczinski F, Grassi-Oliveira R, et al. Insulin dysfunction and allostatic load in bipolar disorder. Expert Rev Neurother 2011;11(7):1017-28
51. Fields RD, Burnstock G. Purinergic signalling in neuron-glia interactions. Nat Rev Neurosci 2006;7(6):423-36
52. Salvadore G, Viale CI, Luckenbaugh DA, et al. Increased uric acid levels in drug-naive subjects with bipolar disorder during a first manic episode. Prog Neuropsychopharmacol Biol Psychiatry 2010;34(6):819-21
53. Machado-Vieira R, Soares JC, Lara DR, et al. A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania. J Clin Psychiatry 2008;69(8):1237-45
54. Srinivasan V, De Berardis D, Shillcutt SD, Brzezinski A. Role of melatonin in mood disorders and the antidepressant effects of agomelatine. Expert Opin Investig Drugs 2012;21(10):1503-22
55. Nurnberger JI Jr, Berrettini W, Tamarkin L, et al. Supersensitivity to melatonin suppression by light in young people at high risk for affective disorder. A preliminary report. Neuropsychopharmacology 1988;1(3):217-23
56. Norris ER, Karen B, Correll JR, et al. A double-blind, randomized, placebo-controlled trial of adjunctive ramelteon for the treatment of insomnia and mood stability in patients with euthymic bipolar disorder. J Affect Disord 2013;144(1-2):141-7
57. Hoertel N, Le Strat Y, Lavaud P, et al. Generalizability of clinical trial results for bipolar disorder to community samples: Findings from the national epidemiologic survey on alcohol and related conditions. J Clin Psychiatry 2013;74(3):265-70
58. Hoertel N, Le Strat Y, Gorwood P, et al. Why does the lifetime prevalence of major depressive disorder in the elderly appear to be lower than in younger adults? Results from a national representative sample. J Affect Disord 2013;doi:pii: S0165-0327(13)00072-4. 10.1016/j.jad.2013.01.017
59. Hoertel N, Le Strat Y, Blanco C, et al. Generalizability of clinical trial results for generalized anxiety disorder to community samples. Depress Anxiety 2012;29(7):614-20
60. Hoertel N, Le Strat Y, De Maricourt P, et al. Are subjects in treatment trials of panic disorder representative of patients in routine clinical practice? Results from a national sample. J Affect Disord 2013;146(3):383-9
61. Bouaziz M, Ambroise C, Guedj M. Accounting for population stratification in practice: A comparison of the main strategies dedicated to genome-wide association studies. PLoS One 2011;6(12):e28845
62. Tordjman S, Drapier D, Bonnot O, et al. Animal models relevant to schizophrenia and autism: Validity and limitations. Behav enet 2007;37(1):61-78
63. Bandura DR, Baranov VI, Ornatsky OI, et al. Mass cytometry: Technique for real time single cell multitarget immunoassay based on inductively coupled plasma time-of-flight mass spectrometry. Anal Chem 2009;81(16):6813-22
64. Schwarz E, Izmailov R, Spain M, et al. Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia. Biomark Insights 2010;5:39-47
65. Brennand KJ, Simone A, Jou J, et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature 2011;473(7346):221-5
66. Doble BW, Woodgett JR. GSK-3: Tricks of the trade for a multi-tasking kinase. J Cell Sci 2003;116(Pt 7):1175-86
67. Calabrese JR, Guelfi JD, Perdrizet-Chevallier C. Agomelatine adjunctive therapy for acute bipolar depression: Preliminary open data. Bipolar Disord 2007;9(6):628-35
68. Fornaro M, McCarthy MJ, De Berardis D, et al. Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: A preliminary open label study. Neuropsychiatr Dis Treat 2013;9:243-51